Literature DB >> 28029152

Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD.

Debbie L Cohen1, Raymond R Townsend1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28029152     DOI： 10.1038/nrneph.2016.189

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis.

Authors:  Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2014-07-28       Impact factor: 10.190

2.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

3.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

4.  Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).

Authors:  Carmen A Peralta; Keith C Norris; Suying Li; Tara I Chang; Manjula K Tamura; Stacey E Jolly; George Bakris; Peter A McCullough; Michael Shlipak
Journal:  Arch Intern Med       Date:  2012-01-09

5.  Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease.

Authors:  Tara I Chang; Grace H Tabada; Jingrong Yang; Thida C Tan; Alan S Go
Journal:  J Hypertens       Date:  2016-02       Impact factor: 4.844

Review 6.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

8.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

9.  Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis.

Authors:  T I Chang; J E Flythe; S M Brunelli; P Muntner; T Greene; A K Cheung; G M Chertow
Journal:  J Hum Hypertens       Date:  2013-06-27       Impact factor: 3.012

Review 10.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.